BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+17.56%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.54B
AUM Growth
+$6.54B
(+5.3%)
Cap. Flow
-$366M
Cap. Flow
% of AUM
-5.6%
Top 10 Holdings %
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18
Top Buys
| 1 |
Immunocore
IMCR
|
$65.3M |
| 2 |
Biohaven
BHVN
|
$46M |
| 3 |
Moderna
MRNA
|
$41.1M |
| 4 |
GE HealthCare
GEHC
|
$40.4M |
| 5 |
Boston Scientific
BSX
|
$30.3M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$108M |
| 2 |
UnitedHealth
UNH
|
$63.2M |
| 3 |
Evolent Health
EVH
|
$42.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$34.5M |
| 5 |
IQVIA
IQV
|
$34M |
Sector Composition
| 1 | Healthcare | 99.06% |
| 2 | Industrials | 0.83% |
| 3 | Energy | 0.03% |
| 4 | Consumer Discretionary | 0.02% |
| 5 | Communication Services | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Zai Lab
ZLAB
$3.48B
| $3.71M | 0.06% |
+135,000
| New | +$3.71M |
|
102
AstraZeneca
AZN
$255B
| $3.48M | 0.05% |
51,600
-33,000
| -39% | -$2.22M |
|
103
SI-BONE Inc
SIBN
$700M
| $2.63M | 0.04% |
+125,200
| New | +$2.63M |
|
104
CVS Health
CVS
$93B
| $2.49M | 0.04% |
31,503
-3,811
| -11% | -$301K |
|
105
McKesson
MCK
$85.9B
| $2.25M | 0.03% |
4,853
-572
| -11% | -$265K |
|
106
Biogen
BIIB
$20.5B
| $2.2M | 0.03% |
8,485
-8,829
| -51% | -$2.28M |
|
|
KRTX
107
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $1.93M | 0.03% |
6,100
-800
| -12% | -$253K |
|
|
108
IQVIA
IQV
$31.4B
| $1.91M | 0.03% |
8,260
-146,960
| -95% | -$34M |
|
109
Recursion Pharmaceuticals
RXRX
$2.02B
| $1.72M | 0.03% |
174,557
+472
| +0.3% | +$4.65K |
|
110
Kosmos Energy
KOS
$803M
| $1.72M | 0.03% |
256,500
-27,500
| -10% | -$185K |
|
111
Labcorp
LH
$22.8B
| $1.61M | 0.02% |
7,089
+101
| +1% | +$23K |
|
112
Certara
CERT
$1.69B
| $1.6M | 0.02% |
91,215
-391
| -0.4% | -$6.88K |
|
113
Cytokinetics
CYTK
$5.98B
| $1.58M | 0.02% |
18,900
-18,200
| -49% | -$1.52M |
|
114
Rhythm Pharmaceuticals
RYTM
$6.75B
| $1.51M | 0.02% |
32,869
-40,431
| -55% | -$1.86M |
|
115
Alkermes
ALKS
$4.95B
| $1.45M | 0.02% |
52,112
-29,588
| -36% | -$821K |
|
116
BridgeBio Pharma
BBIO
$9.91B
| $1.34M | 0.02% |
33,300
-45,400
| -58% | -$1.83M |
|
117
SPDR S&P 500 ETF Trust
SPY
$656B
| $1.24M | 0.02% |
2,600
| – | – |
|
118
Zoetis
ZTS
$67.6B
| $1.14M | 0.02% |
5,790
-672
| -10% | -$133K |
|
119
AbbVie
ABBV
$374B
| $1.04M | 0.02% |
6,727
+1,964
| +41% | +$304K |
|
120
VanEck Gold Miners ETF
GDX
$19.6B
| $1.02M | 0.02% |
33,000
| – | – |
|
121
Xenon Pharmaceuticals
XENE
$2.99B
| $1.01M | 0.02% |
22,000
-1,900
| -8% | -$87.5K |
|
122
Krystal Biotech
KRYS
$4.35B
| $992K | 0.02% |
8,000
-4,500
| -36% | -$558K |
|
123
Vaxcyte
PCVX
$4.17B
| $992K | 0.02% |
15,800
-14,700
| -48% | -$923K |
|
|
INBX
124
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $935K | 0.01% |
24,600
-24,200
| -50% | -$920K |
|
125
Alphabet (Google) Class C
GOOG
$2.79T
| $846K | 0.01% |
6,000
| – | – |
|